Format

Send to

Choose Destination
Trends Cancer. 2017 Jul;3(7):471-474. doi: 10.1016/j.trecan.2017.05.004. Epub 2017 Jun 13.

Targeting ATF5 in Cancer.

Author information

1
Department of Molecular Biosciences, University of California, Davis School of Veterinary Medicine, Davis, CA 95616, USA. Electronic address: jmangelastro@ucdavis.edu.

Abstract

The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.

KEYWORDS:

ATF5; CP-d/n-ATF5; apoptosis; cancer; cell-penetrating peptide; dominant negative

PMID:
28718401
PMCID:
PMC5646417
DOI:
10.1016/j.trecan.2017.05.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center